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FLK1-expressing (FLK1+) mesoderm generates blood
and vessels. Here, we show that combined BMP,
Notch, and Wnt signaling is necessary for efficient
FLK1+ mesoderm formation from embryonic stem
cells (ESCs). Inhibition ofBMP,Notch, andWnt signal-
ing pathways greatly decreased the generation of
FLK1+mesoderm and expression of the Ets transcrip-
tion factorEr71. Enforced expression of ER71 in ESCs
resulted in a robust induction of FLK1+ mesoderm;
rescued the generation of FLK1+ mesoderm when
blocked by BMP, Notch, and Wnt inhibition; and en-
hancedhematopoieticandendothelial cell generation.
Er71-deficientmicehadgreatly reducedFLK1expres-
sion, died early in gestation, and displayed severe
blood and vessel defects that are highly reminiscent
of theFlk1nullmousephenotype.Collectively,wepro-
vide compelling evidence that ER71 functions down-
stream of BMP, Notch, andWnt signals and regulates
FLK1+ mesoderm, blood, and vessel development.
INTRODUCTION
Successful derivation of blood and vessels from embryonic stem
cells (ESCs) for tissue engineering will require a comprehensive
understanding of inductive signals and downstream effectors
involved in blood and vessel lineage development. Ideally, iden-
tification of factors/signals that regulate blood and vessel spec-
ification could facilitate the generation of blood and vessel cells
from ESCs for the treatment of disease and injury. The VEGF/
FLK1 axis is critical for development as well as postnatal and
pathological angiogenesis. In primitive streak stage embryos,
Flk1 is expressed in the extraembryonic and the paraxial-lateralembryonic mesoderm (Dumont et al., 1995; Ema et al., 2006).
Subsequently, its expression is confined to endothelial cells of
the yolk sac blood islands and the developing endocardial
tube. Mice deficient in Flk1 display defects in the yolk sac blood
islands, blood vessels, and endocardium and die around embry-
onic day (E) 9.5 (Shalaby et al., 1995). Vegf+/ embryos also dis-
play blood and vessel defects which phenocopy deficiencies
observed in the Flk1/ embryos (Carmeliet et al., 1996; Ferrara
et al., 1996). This indicates that VEGF is an exclusive ligand for
FLK1 in hematopoiesis and angiogenesis during development
and that VEGF/FLK1 signaling is indispensable for establishment
of the hematopoietic and vascular systems.
FLK1+ mesoderm is developmentally derived from Brachyury/
T-expressing mesoderm and contributes to cells of the circula-
tory system, including blood, vessel, cardiac, smooth, and
skeletal muscle (Faloon et al., 2000; Chung et al., 2002; Ema
et al., 2003; Fehling et al., 2003; Motoike et al., 2003). Despite
the crucial role of FLK1+ mesoderm in the generation of the
circulatory system, the mechanisms that regulate FLK1+ meso-
derm formation and differentiation are poorly understood. Mem-
bers of the Ets family of transcription factors have been impli-
cated in vasculogenesis, angiogenesis, and hematopoiesis
(reviewed in Oikawa and Yamada, 2003). Genetic studies have
revealed distinct roles for each Ets transcription factor in various
developmental stages of hematopoiesis and angiogenesis
(reviewed in Bartel et al., 2000). Recently, etsrp, an Ets transcrip-
tion factor, was identified as a potent inducer of Flk1+ cells in
zebrafish (Sumanas and Lin, 2006). Injection of etsrp mRNA at
the 1 cell stage was sufficient to ectopically induce hemangio-
blast and/or early hematopoietic and endothelial markers, such
as scl and flk1, in a variety of different cell types throughout the
embryo. Conversely, morpholino knockdown of etsrp in zebra-
fish embryos resulted in the complete absence of circulation
due to the failure of angioblasts to migrate, differentiate, and
coalesce into functional vessels. etsrp was downregulated in
zebrafish cloche (clo) mutant embryos, which display defectiveCell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc. 497
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RNA restored expression of vascular markers in clo zebrafish
mutants (Sumanas et al., 2005).
We previously demonstrated that BMP4 was sufficient to gen-
erate FLK1+ mesoderm from differentiating ESCs in serum free
conditions. Yet Noggin, a potent inhibitor of BMPs, could not
completely block FLK1+ cell production from ESCs in serum
(about 40%–50%of the control level) (Park et al., 2004). To better
understand the pathways andmolecular mechanisms involved in
the regulation of FLK1+ mesoderm formation and differentiation,
we testedadditional factors apart fromBMP4byutilizing pharma-
cologic inhibitors of various pathways in the in vitro differentiation
model of ESCs.We also investigated the role of the Ets transcrip-
tion factor Er71, a mouse ortholog of etsrp (Sumanas et al., 2008)
and a gene that is upregulated in the hemangioblast compared to
its progeny (Lugus et al., 2007). We demonstrate that combined
BMP,Notch, andWnt signaling is necessary for FLK1+mesoderm
formation and that ER71 functions downstream of these signals
to regulate FLK1+ mesoderm generation. We also demonstrate
that Er71-deficient mice die around E9.5 due to the failure to
develop blood, vessels, and endocardium. FLK1 expression
was greatly diminished in these mutant embryos. Collectively,
we provide strong evidence that the BMP/Notch/Wnt-ER71 axis
is necessary for blood and vessel formation.
RESULTS
Combined BMP, Notch, and Wnt Signals Are Critical
for the Generation of FLK1+ Mesoderm
To identify additional factor(s) that may cooperate with BMP4 in
FLK1+ mesoderm generation, we assessed pharmacologic
inhibitors of various signaling pathways, including BMP, Notch,
Hedgehog, and Wnt, in differentiating ESCs. Specifically, indi-
vidual or combinations of inhibitors were added on day 1 to
differentiating ESCs, and FLK1+ cells were assessed on day 3,
when Brachyury expression peaks. Thus, FLK1+ cells present
Figure 1. BMP, Notch, and Wnt Inhibition
Blocks the Generation of FLK1+ Cells and
Abrogates Er71 Expression during ESC
Differentiation
ESCswere differentiated in serum (FCS), inhibitors
were added on day 1, and day 3 EBCs were
analyzed for FLK1 expression (A) and subjected
to gene expression (B–D). *p < 0.05 versus FCS.
Genes were normalized against Gapdh, and then
the ratio of the gene quantity (FCS) to gene
quantity (FCS + inhibitors) was determined to yield
fold change shown on the y axis.
at this stage represent mesodermal cells
as they still expressBrachyury and gener-
ate both hematopoietic and endothelial
cells in culture (Faloon et al., 2000; Chung
et al., 2002; Fehling et al., 2003). Noggin,
the Notch inhibitor DAPT (gamma-secre-
tase inhibitor N-S-phenyl-glycine-t-butyl
ester), or the Wnt inhibitor DKK1 (dick-
kopf-1) reduced, to a varying degree, FLK1+ cells, whereas cy-
clopamine, a small-molecule antagonist of the Hedgehog path-
way, did not (Figure 1A). Treatment of both Noggin and DAPT
reduced FLK1+ cells even greater, by more than 80%. Impor-
tantly, the addition of all three inhibitors, Noggin + DAPT +
DKK1, nearly completely abolished FLK1+ cells. Notably, Flk1
expression was also completely blocked by Noggin + DAPT +
DKK1 (Figure 1B). In the presence of Noggin, DAPT, or DKK1,
the expression of Id genes and Gata2, Hey1, or Lef1,
respectively, was reduced, indicating that Noggin, DAPT, or
DKK1 successfully inhibited the respective signaling pathway
(data not shown). Moreover, the total cell number after inhibitor
treatment did not change significantly.
To better understand the genetic program mediated by BMP,
Notch, and Wnt signaling, we examined genes that are
expressed during germ layer formation and patterning
(Figure 1C) (Gadue et al., 2006; Lindsley et al., 2006). Noggin +
DAPT + DKK1 treatment significantly inhibited the expression
of posterior primitive streak genes, including Brachyury (T),
Tbx6 and Fgf8, and the anterior primitive streak genes, Gsc
and Cer1. Intriguingly, the expression of another anterior primi-
tive streak gene, Foxa2, was not changed considerably by these
inhibitors. Genes that are expressed in mesoderm and endo-
derm, such as Mesp1, Mesp2, Pdgfra, Gata4, Sox17 and Hnf4,
were almost completely suppressed by these inhibitors. Con-
versely, the expression of ectoderm genes, such as NeuroD,
Fgf5 and Pax6, was upregulated by Noggin + DAPT + DKK1
treatment. Thus, consistent with previous studies (Lai, 2004;
Tam and Loebel, 2007), BMP, Notch and Wnt pathways are
ciritical for mesoderm and endoderm formation and patterning.
Er71 Expression Pattern in Developing Embryo
and Differentiating ESCs
We previously reported that the expression of the Ets transcrip-
tion factor Er71 was greatly enriched in the hemangioblast
population (FLK1+SCL+ cells from day 2.75 embryoid bodies,
EBs, differentiated ESCs) compared to their progeny, blast cells498 Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc.
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etsrp (Sumanas et al., 2008), we assessed the possbility that
ER71 could modulate FLK1+ mesoderm development in the
mouse. The expression of Er71 was decreased in differentiating
ESCs when treated with Noggin, DAPT, or DKK1 (Figure 1D).
Importantly, Er71 was diminished by more than 80%, when
Noggin + DAPT + DKK1 were included in the differentiation me-
dia. This suggested that Er71 is downstream of BMP, Notch, and
Wnt signaling and could regulate FLK1+ mesoderm generation.
Er71 has been shown to be mainly expressed in the adult testis
(Brown and McKnight, 1992). As its embryonic expression and its
role indevelopment isnot known,wefirstevaluated theexpression
pattern of Er71 by in situ hybridization. Er71 was expressed in the
primitive streak, embryonicmesoderm, amnion, allantois, and yolk
sac blood islands in E7.5 embryos (Figure 2A). At later embryonic
stages (E8.25–E9.5), Er71 expression was mainly detected within
major vessels, including the dorsal aorta and branchial arch
(Figure 2A). Next, we examined the expression kinetics of Er71 in
differentiating ESCs in relationship to Brachyury. The onset of
Er71 expression in differentiating ESCs was detectable at the
time of Brachyury expression and preceded that of Flk1
(Figure 2B) (Lugus et al., 2007; data not shown). Similar to Bra-
chyury expression, Er71 expression within differentiating ESCs
was transient and became undetectable 4 days after differentia-
tion.More importantly, when day 2.75 EBcells (EBCs) were sorted
asFLK1+ or FLK1,Er71wasmainly expressedwithin FLK1+ cells,
notFLK1, suggesting thatER71potentially regulatesFlk1expres-
sion (Figure 2C). As we previously reported (Lugus et al., 2007),
Er71 was greatly downregulated within blast cells compared to
a cell population enriched for hemangioblasts (FLK1+hCD4+). Col-
lectively, these data indicate that Er71 is expressed transiently in
developing embryos and differentiating ESCs and that its expres-
sion is mainly restricted to FLK1+ mesoderm and its derivatives.
ER71 Is a Potent Inducer of FLK1+ Mesoderm
We assessed the role of ER71 in FLK1+ mesoderm generation
and differentiation in the ES/EB system. To this end, we gener-
ated an inducible ER71 (iER71) ESCs by targeting the tet-
responsive locus of A2Lox ESCs (an E14Tg2a-based ESC line)
with the Er71 cDNA, fused to a V5 tag at the 30 end (Figure 3A).
Similar to Ainv15 (Kyba et al., 2002), A2Lox cells were engi-
Figure 2. Er71 Is Expressed Transiently in Early Embryos
and Differentiating ESCs
(A) In situ hybridization analysis of Er71. PS, primitive streak; Bl,
blood islands; Al, allantois; Am, amnion; A, anterior; P, posterior;
D, dorsal; V, ventral.
(B and C) Er71 expression analysis. RNA obtained from differenti-
ating ESCs (B) or various cell populations sorted from day 2.75
EBCs (C) was used to examine Er71expression. The value normal-
ized against Gapdh is shown on the y axis.
neered to constitutively express the reverse tetracy-
cline transactivator (rtTA) from the Rosa26 locus
(data not shown). In addition, these ESCs contain a tar-
geting site upstream of the HPRT locus, such that
a transgene is under the regulation of the tetracycline
operator after site-specific recombination. To track
SCL-expressing cells, we generated an A2Lox derivative in
which nonfunctional human CD4 (hCD4) was knocked in into
theScl locus (Lugus et al., 2007). After the correct targeting event
was confirmed by a tet-responsive locus/cDNA vector-specific
PCR (data not shown), inducible Er71 expression was verified
by RNA analyses. The addition of doxycycline (Dox, 1 mg/ml, at
which concentration no cytotoxicity was observed, data not
shown) resulted in about 3-fold induction of Er71 RNA expres-
sion in differentiating iER71 ESCs compared to noninduced cells
in serum (Figure 3B). The fold change in Er71 expression was
even greater (18 fold) when Er71 was induced in serum-free
conditions (i.e., SR media). Two independent iER71 ESC lines
showed similar phenotypes.
We first investigated the ER71-mediated transcriptional pro-
gram. To this end, iER71 ESCs were differentiated in serum or
SR, ER71 was induced at day 1 (day 2 for SR), and the gene
expression profile was analyzed 2 days later. The expression of
Brachyury (mesoderm), Foxa2 (endoderm), or NeuroD (ectoderm)
was similar in ER71-induced cells as compared to noninduced
(<2-fold change) (Figure 3C). This indicates that enforced Er71
expression did not significantly alter the expression of genes in-
volved in germ layer formation. Importantly, genes expressed in
hematopoietic as well as endothelial cells were increased. The
fold increase of these genes was greater in serum-free conditions
compared to serum, potentially due to the higher fold of Er71 in-
duction.Consistentwith thegeneexpressionstudies,ER71 induc-
tion in serum free conditions led to a de novo generation of FLK1+
cells (Figure 3D; 47% ± 4% versus 0.75% ± 0.15%; p < 0.0001;
n = 3). ER71 and BMP4 together generated slightly more FLK1+
cells compared to ER71 alone (56.5% ± 2% versus 46.6% ±
3.7%; p < 0.05; n = 3). ER71 also enhanced FLK1+ cell generation
in serum (Figure 3E, 68%± 7%versus 45%± 3%; p < 0.05; n = 3).
To determine if ER71 truly functions downstream of BMP,
Notch, and Wnt pathways to regulate FLK1+ mesoderm genera-
tion, we determined if ER71 could rescue the generation of FLK1+
cells when the respective pathways were blocked. To this end,
iER71 ESCs were differentiated in serum; Noggin, DAPT, and/
or DKK1 were added on day 1, ER71 was induced from day 1,
and FLK1+ cells were analyzed on day 3. As shown, ER71 could
rescue the generation of FLK1+ cells inhibited by Noggin, DAPT,
or DKK1. More importantly, ER71 was sufficient to rescue the
generation of FLK1+ cells inhibited by Noggin + DAPT + DKK1Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc. 499
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(A) Schematic diagram of the inducible ER71 (iER71) ESCs used, with indicated loci carrying alterations allowing for production of the rtTA, expression of the Er71
cDNA, and generation of hCD4 as a surrogate marker for Scl.
(B and C) Er71 induction upon Dox treatment and the ER71-mediated transcriptional program. iER71 ESCs were differentiated for 1 day in serum or for 2 days in
SR and then treated with 1 mg/ml Dox for an additional 2 days. RNA was prepared and used for qRT-PCR. Genes were normalized againstGapdh, and the ratio of
the gene quantity (+Dox) to gene quantity (Dox) was determined to yield normalized fold change.
(D) iER71 ESCs were differentiated as described. BMP4 was added on day 2. The resulting cells were FACS analyzed for FLK1. Numbers in insets indicate the
percentage of FLK1+ cells.
(E) iER71 ESCswere differentiated in serum as described. Noggin, DAPT, and DKK1, singularly or in combination, were added on day 1 of differentiation. Doxwas
added on day 1, and FLK1+ cells were analyzed on day 3. Numbers in insets indicate the percentage of FLK1+ cells.
(F) Upper panel: schematic diagram of the Flk1 promoter used for luciferase assay. Diamonds indicate potential Ets binding sites (red in sense and blue in
antisense). For mutagenesis, potential Ets sites GGAA/T (sense) and A/TTCC (antisense) were mutated to TTAA/T and A/TTTT, respectively. Lower panel:
293T cells were transfected with pGL3 or pGL3-Flk1 promoter-luciferase reporter plasmid (WT or MT) with or without pCS3-Myc-Er71. Firefly luciferase activity
was normalized by Renilla luciferase activity.
(G) iER71 ESCs differentiated in serum in the presence of Dox were crosslinked, sonicated, and subjected to ChIP assay. Numbers on the x axis indicate the
locations of amplicons of each qPCR primer set on Flk1. The value normalized against IgG IP values is shown on the y axis.(Figure 3E). This argues that ER71 acts downstream of BMP,
Notch, and Wnt and regulates FLK1+ mesoderm generation.
ER71 Directly Activates Flk1 Expression
Based on the findings that ER71-induced FLK1+ mesoderm
(Figures 3D and 3E) is a potent transcriptional activator (De
Haro and Janknecht, 2002; Knebel et al., 2006) and that the
Flk1 promoter/enhancer region contains putative Ets binding
sites (Kappel et al., 2000; Elvert et al., 2003), we tested if ER71
could directly induce Flk1 expression. To this end, Flk1
promoter-luciferase constructs were transiently transfected in
293T cells with or without a construct expressing ER71, and
luciferase activity was assayed. As shown, ER71 robustly
activated the492 to +39 Flk1 promoter, which contains 9 puta-500 Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc.tive Ets binding sites (Figure 3F; Figure S1A available online).
ER71 could also induce Flk1 expression in endothelial cells
(Figure S1B). Individual mutations of the 9 putative sites in the
Flk1 promoter reduced its response to ER71 (Figure 3F). More
importantly, multiple mutations including sites 1–4 or 5–9 in the
Flk1 promoter effectively abolished its response to ER71.
To examine whether these conserved sites were relevant
in vivo, weused chromatin immunoprecipitation (ChIP) tomeasure
DNA binding by ER71. As shown in Figure 3G, the Flk1 promoter
region was enriched for H3K4Me3, indicating that this region of
DNA is actively being transcribed in day 3 EBs. Additionally,
we found ER71 binding to this region of the promoter. The en-
richment of ER71 occupancy at the 174 to 81 region was
greater compared to other promoter regions. As expected, the
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lial Cell Generation
(A) iER71ESCsweredifferentiated inSRorserum,andDox (1mg/ml)
wasaddedonday3.BMP4andVEGFA165wereaddedonday2and
day 3, respectively. In all cases, cellswere FACS analyzed for FLK1,
hCD4, or VE-Cadherin (VE-Cad) expression on day 5 (FCS) or day 6
(SR). Left panels: numbers in a given box indicate the percentage of
cells that are FLK1hCD4 (lower left), FLK1+hCD4 (lower right),
FLK1+hCD4+ (upper right), or FLK1hCD4+ (upper left). Right
panels: numbers in a given box indicate the percentage of
VE-Cad+ cells.
(B) iER71 cells differentiated for 6 days in serum free conditionswith
indicated factors were replated inmethylcellulosemediumcontain-
ing hematopoietic cytokines. Colonies were counted 5–7 days after
replating. EBCs generated in SR alone gave rise to few erythoid
colonies (average = 10.7) with no Mac or E/M colonies. Error bars
indicate standard deviations from three independent experiments.
Ery, Erythrocytes;Mac,Macrophages; E/M, Erythroid/Macrophage
colonies.
(C) Transient expression of ER71 increases the generation of
primitive erythroid progenitors. Dox was added to the culture at
the indicated day and kept until day 4 or washed out (WO) the
next day. On day 4, iER71 EBCs were replated for primitive
erythroid colonies. Colonies were counted 4 days later. Data
represent four independent experiments.
(D) Hematopoietic and endothelial cell development upon ER71 overexpression using embryo-derived cell culture. Pooled embryos between E8.0 and E8.5 were
dissociated into single cells and infected with MSCV or MSCV-ER71-IRES-GFP virus. Subsequently, cells cultured on OP9 cells were subjected to hematopoietic
colony replating (upper; values are mean ± SEM from two independent experiments) or PECAM1 staining (lower; representative images are shown).50.4 kb region, which is outside of the Flk1 locus, was not oc-
cupied by ER71. The +20 to +239 bp region generated a similar
result to that of the 50.4 kb region, indicating that ER71 mainly
occupies the 492 to +39 bp region of the promoter. Collec-
tively, we conclude that ER71 promotes FLK1+ mesoderm for-
mation by directly activating Flk1 gene expression.
ER71 Is Sufficient to Induce Blood and Endothelial Cell
Differentiation from ESCs
Enforced ER71 expression during mesoderm formation resulted
in an increase of genes expressed in the endothelial lineage (Pe-
cam1, Tie2, and VE-cadherin) as well as hemangioblast and/or
hematopoietic genes (Gata1, Gata2, and Scl) (Figure 3C). The
increased expression of these genes could be due to enhanced
hematopoietic and/or endothelial differentiaion by ER71. To
determine if ER71 additionally plays a role in blood and endothe-
lial cell differentiation from FLK1+ mesoderm, iER71 ESCs were
differentiated, ER71 was induced from day 3, and hCD4+ (SCL+
hematopoietic progenitors), as well as FLK1+ or VE-cadherin+
cells (endothelial cells), were assessed on day 5 and onward
by FACS analyses (Figure 4; data not shown). As shown, ER71
induction alone in serum-free conditions was sufficient to gener-
ate SCL+ hematopoietic (76% ± 3% versus 7% ± 1%), FLK1+
(33% ± 1% versus 8% ± 3%), or VE-Cadherin+ (32% ± 7.5%
versus 2.6% ± 1%) endothelial cells (Figure 4A, upper panels).
The generation of functional hematopoietic cells by ER71 in
serum-free conditions was confirmed by replating EBCs after
Dox treatment (Figure 4B). Previously, we reported that BMP
and VEGF were sufficient for blood generation in serum free
conditions (Park et al., 2004). Importantly, the level of SCL+ cells
or the actual hematopoietic progenitor number generated by
ER71 was similar to that by BMP and VEGF (Figures 4A and
4B). In serum, ER71 induction led to a greater increase inFLK1+ or VE-Cadherin+ endothelial cells (64% ± 1% versus
11% ± 1%; 70% ± 5% versus 10% ± 2%; p < 0.001; n = 3,
respectively), with a concurrent decrease in SCL+ hematopoietic
cells (44% ± 11% versus 72% ± 1%; p < 0.05; n = 3) (Figure 4A,
lower panels). Factor(s) present in serum could have contributed
to this outcome. Intriguingly, an increase in primitive hematopoi-
esis was seen with a pulse induction from day 2 to 3 (Figure 4C).
Continuous expression of ER71 from day 2 or 3 of EB culture
inhibited primitive hematopoiesis. Potentially, this reflects an
enhancement of FLK1+ mesoderm and/or hemangioblast cell
population from the pulse of Er71 induction.
Next, we utilized an embryo-derived cell culture (Zeigler et al.,
2006) to further determine the role that ER71 might have in
hematopoietic and endothelial cell generation. As shown, em-
bryo cells that were infected with MSCV-ER71 virus displayed
a robust endothelial cell generation compared to control retrovi-
ruses as judged by PECAM1 antibody staining (Figure 4D). The
number of hematopoietic colonies that were generated did not
show significant change. This indicates that ER71 can addition-
ally promote endothelial cell progenitor proliferation and/or
differentiation.
Generation of Er71/ Mice
Our data demonstrate that ER71 is sufficient to generate FLK1+
mesoderm, blood and endothelial cells. To assess the in vivo
role of ER71, we generated mice lacking Er71 and examined
blood and vessel development. The targeted mutation deleted
exons 5 to 7, which encompasses the ETS binding domain of
the protein (Figure 5A). After electroporation, puromycin selec-
tion, and screening, 9 correctly targeted clones were identified
(Figure 5B). The mutant allele from two independent clones
was transmitted through the germline after crossing chimeric
mice with C57BL/6 females.Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc. 501
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(A) Structures of the mouse Er71 gene, the pGKpuro targeting vector, and the targeted allele after homologous recombination. Black boxes depict exons. The
flanking genomic probes used for Southern blot analysis are indicated with gray squares. Only the EcoRI restriction enzyme site relevant to the targeting construct
and screening strategies is shown.
(B) Southern blot analyses of representative Er71+/ ESC clones and genotyping of ESCs and E9.5 embryos by PCR. Thewild-type (15.8 kb) and themutant allele
(8.5 kb) detectedwith the 50 external probe, aswell as the wild-type (15.8 kb) and themutant allele (6.8 kb) detected with the 30 external probe, after EcoRI digest are
shown. PCR products of the wild-type Er71 allele (1000 bp product from primers 1 and 2) and the mutant allele (700 bp product from primers 1 and 3) are shown.
(C) Gross morphology of Er71/ embryos at E9.5. ([a] and [c], embryo proper; [b] and [d], yolk sac). Scale bars, 200 mm.
(D) Gene expression analysis. RNA was prepared from E8.5 (n = 2) embryos and subjected to qRT-PCR. The value normalized against Gapdh is shown on the y
axis.Mice heterozygous for the Er71 mutation were viable, fertile,
and phenotypically indistinguishable from wild-type mice.
However, no homozygotes were obtained from heterozygous
intercrosses at weaning, suggesting that Er71/ mice were
embryonically lethal. To identify the developmental stage at
which lethality occurs, embryos from heterozygote intercrosses
were examined at different gestational stages. The Mendelian
distribution of Er71/ embryos was normal at E8.5 and there
were no noticeable differences between the wild-type and the
mutant embryos. Homozygous embryos were still obtained
with the expected Mendelian frequency at E9.0 (Table S1).
However, Er71/ embryos at E9.0 were significantly smaller
in size than their wild-type littermates (data not shown). At
E9.5, the Mendelian frequency of Er71/ embryos was
reduced significantly, and all mutant embryos were notably
pale and showed growth retardation (Figure 5C). Although large502 Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc.vitelline blood vessels were normally seen in the wild-type yolk
sacs, Er71/ yolk sacs were pale and no blood vessels were
seen. No Er71/ embryos were recovered beyond E11.0.
Mice Lacking Er71 Display Hematopoietic
and Vascular Defects
Histological analyses revealed that E7.5 to E8.5 mutants were
morphologically normal and gastrulation occurred normally,
generating all three germ layers (Figure S2A; data not shown).
Consistent with these observations, the expression level of
genes expressed in primitive streak, mesoderm, endoderm, or
ectoderm was not greatly changed between the wild-type and
mutant embryos at E8.5 (Figure 5D). We further examined Bra-
chyury expression by in situ hybridization, which was expressed
normally in the axial mesoderm of mutant embryos (Figure 5D;
data not shown). Moreover, sagittal sections showed that
Cell Stem Cell
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(A and B) H&E staining of E8.5 embryos. The boxed area is shown at higher magnification. Bl, blood island; DA, dorsal aorta. Scale bars, 50 mm.
(C) Sagittal sections of wild-type and Er71/ hearts from E9.5 embryos. Ec, endocardium; Mc, myocardium. Scale bars, 50 mm.
(D) Sagittal sections of the placenta of E9.5 embryos. Higher magnification of the labyrinth layers of the wild-type and Er71/ placentas is shown in the box. dec,
maternal decidual tissue; sp, spongiotrophoblast layer; la, labyrinth layer. Scale bars, 200 mm.somites were present in E9.0 mutants (Figure S2B). Thus, the
embryonic lethality of Er71/mice is not due to general defects
in mesoderm formation and differentiation or axial patterning.
Histological examination demonstrated that although yolk sac
blood islands were readily detectable in the wild-type, no such
structures were seen in the mutant yolk sac, nor did the dorsal
aorta or endocardium form in the mutant embryos (Figure 6;
Figure S2). The immunohistochemical staining pattern of smooth
muscle a-actin was similar between the wild-type and mutant
embryos (Figure S2C), suggesting that cardiomyocytes devel-
oped relatively normally. Similar expression levels of smooth
muscle a-actin andmyosin heavy-chain (MHC) genes, as judged
by quantitative RT-PCR, from E9.0 hearts further support this
notion (Figure S3B). Since blood vessels could not be detected
in themutant embryo proper or their yolk sacs, we also examined
the placenta. During development, the allantois attaches to the
chorionic plate in the formation of a functional placenta, followed
by vascular invasion of the labyrinth layer. In wild-type embryos,
blood vessels containing many nucleated erythrocytes normally
invaded and integrated into the labyrinth layer of the developing
placenta (arrowhead in Figure 6D). In contrast, the labyrinth
formation in Er71/ embryos was retarded and vascularization
had not started in the placenta. Consequently, the labyrinth layer
of the mutant placenta is significantly decreased in thickness
(Figure S2D). No nucleated erythrocytes were detected in the
mutant placenta, although enucleated erythrocytes of maternal
origin were readily detectable. There was a higher level of TUNELstaining in Er71 mutants as compared to wild-type embryos at
E9.5, indicating that without proper blood and vessels, the
embryos cease to develop and undergo apoptosis (Figure S2E).
To further characterize blood defects in Er71/ embryos, we
subjected E9.0 embryos to benzidine staining. As shown, the
presence of erythrocytes in the E9.0 wild-type embryos was
readily confirmed by benzidine staining, although no such stain-
ing was found in the mutant embryos (Figure 7A). No primitive
erythroid colonies formed when E8.5 Er71/ yolk sacs were
subjected to hematopoietic replating. (Figure 7A). These results
demonstrate the absence of hematopoietic progenitors in the
mutant yolk sacs.
We next confirmed the complete absence of the vasculature in
Er71/ embryos by immunohistochemistry. At E7.5, FLK1 stain-
ing was readily detectable in the primitive streak, blood islands,
allantois, and amnion. However, no such staining was found in
the mutant embryos (Figure 7B). At E8.5, FLK1 staining was
detectable in the vasculature of the head, trunk, heart, and inter-
somitic regions. No FLK1 staining was detectable in the mutant
embryos (Figure 7C). Immunofluorescent staining with FLK1 and
PECAM1 antibodies also confirmed the absence of vasculature
in the mutant yolk sac. At E9.5, large, well-branched vitelline
blood vessels, which are linedwith PECAM1-positive endothelial
cells, were normally seen in wild-type yolk sacs, but not in
mutant yolk sacs (Figure 7D). Well-organized blood vessels
were also detectable, as judged by PECAM1 and FLK1 staining
in the wild-type brain, heart, and intersomitic regions, but not inCell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc. 503
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(A) Left: benzidine staining. Scale bars, 200 mm. Right: hematopoietic progenitor assay. Cells prepared from E8.5 YSwere replated intomethycellulose containing
hematopoietic cytokines.
(B) FLK1 expression in E7.5 embryos. FLK1 is expressed in primitive streak (PS), blood islands (Bl), allantois (Al), and amnion (Am) in the wild-type, but not in the
mutants. Scale bars, 50 mm.
(C) FLK1 expression in E8.5 embryos. Upper: whole mount FLK1 staining of the embryo proper. Scale bars, 200 mm. Lower: immunofluorescent FLK1 (green) and
PECAM1 (red) staining of the yolk sac. Nuclei were stained with DAPI (blue). Em, embryo proper. Scale bars, 50 mm.
(D) Whole-mount PECAM1 or FLK1 staining of E9.5 embryos. The boxed area is the vasculature of the yolk sac, brain, heart, and intersomitic regions at higher
magnification. Scale bars, 200 mm.Er71/ embryos. Collectively, we conclude that ER71 is
essential for FLK1+ cell formation, blood, and endothelial cell
development.
DISCUSSION
Flk1, a receptor tyrosine kinase, is a critical gene involved in
blood and vessel development as evidenced by knockout stud-
ies. Fate mapping studies have demonstrated that FLK1+ meso-
derm contributes to hematopoietic, endothelial, skeletal, and
smooth muscle cells. FLK1 continues to play a critical role in
endothelial cells in the adult. Therefore, understanding the
upstream signals and molecular mechanisms that regulate Flk1
expression is essential for delineating the pathways involved in
blood and vessel differentiation during embryogenesis as well
as postnatal angiogenesis. We provide evidence that inhibition
of BMP, Notch, or Wnt pathways individually could partially
block the generation of FLK1+ cells, while inhibition of all three504 Cell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc.pathways completely blocked the generation of FLK1+ cells.
Our studies are supported by recent studies that Wnt signaling
is important for ES-derived mesoderm and hematopoietic devel-
opment (Lindsley et al., 2006; Lengerke et al., 2008; Nostro et al.,
2008). Intriguingly, Lindsley et al. (2006) showed that DKK1 addi-
tion to differentiating ESCs could almost completely block
Brachyury expression and formation of FLK1+ mesoderm. In
our hands, purified recombinant DKK1 could not completely
abrogate generation of FLK1+ mesoderm. It is likely that the un-
defined composition of the conditioned media used as a source
for DKK1 by Lindsley et al. could have contributed to this
discrepancy. In examining Notch signaling, the expression of
tamoxifen-inducible, constitutively active Notch1 in ESCs could
inhibit generation of FLK1+ mesoderm (Schroeder et al., 2006).
Potentially, the prolonged, constitutive Notch activity, which is
known to block differentiation of stem cells, could have contri-
buted to this observation. As Er71 is expressed at low levels in
adult endothelial cells (data not shown), it will be exciting to
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BMP, Notch, and Wnt signaling during pathologic angiogenesis.
Previous studies indicate that Ets1 could transactivate the Flk1
promoter andmutation of either of two Ets binding sites,141 to
136 bp and 71 to 66 bp, impaired Flk1 promoter activity by
Ets1 in vitro (Kappel et al., 2000; Elvert et al., 2003).Moreover, the
mutation of the 141 to 136 Ets site resulted in a reduced re-
porter activity in the vasculature of transgenic embryos. Intrigu-
ingly, this site (no. 6 in Figure 3F) was also critical for ER71-me-
diated transactivation of Flk1. ER71 is a unique Ets factor within
the Ets family of transcription factors, as it shares no homology
with any other Ets members other than its DNA-binding domain
(Brown and McKnight, 1992; De Haro and Janknecht, 2005).
Our analyses of Er71 null embryos and ESC differentiation dem-
onstrate that ER71 is critical for Flk1 expression as well as hema-
topoietic and vascular development. As such, the hematopoietic
and vascular defects seen in Er71 null mice are most similar to
those of Flk1-deficient mice. As no defects in hematopoietic
and vascular development were observed in Ets1 null mice, we
propose that ER71 is the genuine Ets transcription factor that
regulates Flk1 expression during early embryonic development.
To our knowledge, ER71 is the first transcription factor that
shows a nonredundant, indispensable function in the regulation
of blood and vessel development in the mouse.
Pham et al. (2007) reported that the ENU-generated y11 zebra-
fish mutants have a mutation in the etsrp gene. etsrpy11 mutants
display defects in vascular morphogenesis and angiogenesis.
Specification of angioblasts during initial vasculogenesis occurs
normally in thesemutants. Importantly, expression of endothelial
and hematopoietic genes, including flk1, flt4, gata1, and gata2,
were all reduced in etsrpy11mutants. In the developing zebrafish
vasculature, the Ets factors etsrp, fli1, fli1b, and ets1 are all
expressed in an overlapping manner spatially and temporally.
Morpholino knockdown of individual ets genes resulted in partial
or no defects in endothelial differentiation, but combined reduc-
tion of all four ets genes, etsrp, fli1, fli1b, and ets1, led to dramatic
decrease in endothelial cells. These studies suggest that Ets
factors perform overlapping function in zebrafish vascular devel-
opment. This is in sharp contrast to our findings that ER71 inac-
tivation results in a complete block of hematopoietic and vascular
development in mice. Whether etsrp function is duplicated in ze-
brafish or whether zebrafish vascular development also requires
the new fourth VEGF receptor (VEGFR4) that is lost in mammals
(Bussmann et al., 2007) should be investigated in the future.
Recent studies (Schoenebeck et al., 2007) suggest a critical
regulatory relationship between the nascent blood/vessel versus
cardiac program. Specifically, scl and etsrp injection into zebra-
fish embryos resulted in the expansion of hematopoietic and
endothelial specification with a concurrent reduction of the myo-
cardial field. Conversely, knockdown of scl and etsrp resulted in
an expansion of the boundaries of hand1 expression, suggesting
reciprocal regulation between the hematopoietic/vascular and
cardiovascular systems. Intriguingly, enforced ER71 expression
in ESCs resulted in an increase in genes expressed in the blood
and endothelial cell lineages and a decrease in genes expressed
in the cardiac lineage (Figure 3E). Conversely, genes expressed
in hematopoietic as well as endothelial cells were downregu-
lated, and cardiogenic genes were upregulated in the Er71
mutant embryos (Figure S3). Quantitative RT-PCR betweenwild-type and mutant E9.0 hearts confirmed that some of these
genes were upregulated in the mutant hearts, although the fold
difference was not significant. Future studies on downstream
mediators of ER71 in the regulation of hematopoietic/vessel
versus cardiac differentiation are warranted.
EXPERIMENTAL PROCEDURES
Cell Culture and Flow Cytometry
ESC culture, in vitro differentiation, hematopoietic replating, and flow cytom-
etry were performed as described previously (Park et al., 2004; Lugus et al.,
2007). Factors were used as follows: 5 ng/ml BMP4, 10 ng/ml VEGF165,
11 nM DKK1, 1 nM Noggin, 2 mM DAPT (R&D systems), 3 mM Cyclopamine
(TRC-Canada), and 1 mg/ml Doxcycline (Sigma).
Generation of the ER71 Knockout Mice and Genotyping
Cloning of a 12 kb genomic XbaI fragment encompassing all exons of Er71 has
been described previously (De Haro and Janknecht, 2005). We then subcloned
6.8 kb of the XbaI-SalI genomic fragment (50 homologous arm) and 3.1 kb of
the SpeI-XbaI fragment (30 fragment) into pBluescript(+) KS vector and then
inserted puro, phosphoglycerokinase (pgk)-puromycin poly(A) resistance
cassettes, and DT-A genes, leading to disruption of exons 5, 6, and 7 of mouse
Er71. The Er71-pGK-puro vector was linearized with NotI and introduced into
ESCs by electroporation using a Gene Pulser (1 pulse of 0.25 kV and 500 mF;
Bio-Rad). Resistant ESC clones grown in conditioned medium were isolated
after 8 days of culture. Homologous recombination was confirmed by South-
ern blot analysis of the genomic DNA prepared from ESC clones using external
probes, as indicated in Figures 5A and 5B. Genotyping of embryos and mice
was performed by PCR using primers Er71-L(ACGTAGAAGGCTGCTGGAAA),
Er71-R(GCAGTTTGCAGCCTCTTACC), and pGK-3(GCACGAGACTAGTGAG
ACGTGCTAC). The products are 1000 bp (wild-type allele) and 700 bp (puro
allele).
Whole-Mount In Situ Hybridization
Whole-mount in situ hybridization was performed as described previously
(Manley and Capecchi, 1995). The mouse T probe was a gift from Dr. Y.
Kong (Pohang University of Science and Technology, Korea). The mouse
Flk1 or Er71 in pBS SK() was linearized and transcribed with T7 (Ambion).
Probes were labeled with digoxigenin, and signals were detected by alkaline
phosphatase-conjugated anti-digoxigenin antibody.
Histology and Immunohistochemistry
Immunostaining of embryos was performed as described previously (Li et al.,
2003). Briefly, embryos were fixed in 4%paraformaldehyde, bleachedwith 5%
H2O2, blocked in 2%bovine serum albumin, incubated with primary antibodies
and second antibody sequentially, and stained with the DAB kit (DAKO). Anti-
bodies used were anti-PECAM1 (BD), anti-FLK1 (BD), and HRP-conjugated
goat anti-rat IgG (Jackson ImmunoResearch).
Retrovirus Production
Phoenix packaging cells were maintained in DMEM/10% FCS/1% L-Gluta-
mine. On day 0, 1.25 3 106 cells were plated on gelatinized 6 cm dishes. On
day 1, 3 mg of MSCVpac (control) or MSCV-ER71-IRES-GFP was used to
transfect cells with FuGene 6 (Roche), and 18–24 hr later, media was changed.
Cells were then grown at 32C for 24 hr, and media was recovered and filtered
with a 0.45 mm filter before being used to infect embryo-derived cells.
Coculture of Embryonic Cells with OP-9 Cells
Coculture of embryonic cells with OP-9 cells was previously described (Zeigler
et al., 2006). Briefly, embryos between E8.0 and E8.5 were dissected, dissoci-
ated, and infected with MSCV or MSCV-ER71-IRES-GFP viral supernatant in
the presence of protamine (10 mg/ml). After ER71 retroviral infection, duplicate
of one half equivalent embryo cells were cultured on mitomycin C-treated OP9
cells in a-MEM containing 10% FCS supplemented with 1% of IL-3, 1% of KL,
10 ng/ml of human thrombopoietin (TPO), 2 unit/ml of EPO, 5 ng/ml of G-CSF,
20 unit/ml of GM-CSF, and 10 ng/ml of VEGFA165. On day 4 of culture, cells
from one-half duplicate were replated into methylcelluose containingCell Stem Cell 2, 497–507, May 2008 ª2008 Elsevier Inc. 505
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plicate were stained with a-PECAM1 (CD31) antibody (1:30, PharMingen)
overnight at 4C. The following day, cells were incubated with alkaline phos-
phatase-conjugated anti-Rat IgG (1:250, Zymed), and signals were visualized
with the NBT/BCIP kit (Promega).
Quantitative Real-Time PCR
RNA preparation and cDNA synthesis were previously described (Park et al.,
2006; Lugus et al., 2007). Primer sequences used in this study are provided
in Table S2.
Chromatin Immunoprecipitation
ChIP assays were performed as previously described (Im et al., 2004). Briefly,
iER71-V5 ESCs differentiated in serum, Dox was added on day 1, and EBs
were collected on day 3 and crosslinked with 1% formaldehyde. Cells were
lysed, and chromatin was fragmented to 500 bp by sonication. The chroma-
tin slurry was incubated with anti-mouse V5 or anti-rabbit H3K4Me3 anti-
bodies. Anti-mouse IgG or anti-rabbit IgG, respectively, was used as a control.
The immunoprecipitated DNA fragments were recovered and subjected to
qPCR using the primers listed in Table S3.
Cloning of Mouse Flk1 Promoter and Reporter Assays
The PCR-amplified murine Flk1 promoter fragment from 129/Sv mouse ESC
genomic DNA was inserted into the XhoI and HindIII sites of pGL3-Basic
and verified by sequencing. 293T cells (1 3 105/well of a 6-well plate) were
transfected with 250 ng Er71 expression plasmid (pCS3-Myc-ER71), 50 ng
pGL3-mFlk1 promoter constructs, and 25 ng pRL-CMV byCaCl2 precipitation.
Forty-eight hours later, cells were harvested, and luciferase activity was mea-
sured using the Dual-Luciferase reporter assay system (Promega) according
to the manufacturer’s instructions. Firefly luciferase values were divided by
Renilla luciferase values to calculate transfection efficiency. Primers used for
the construct of the 492 to +39 Flk1 promoter were listed in Table S3.
Statistics
The results of qRT-PCR, FACS analysis, and hematopoietic replating were an-
alyzed by Student’s t test. p < 0.05 was considered significant.
SUPPLEMENTAL DATA
The Supplemental Data include three figures and three tables and can be
found with this article online at http://www.cellstemcell.com/cgi/content/full/
2/5/497/DC1/.
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